Matthew Dowling is a seasoned bioengineering professional with a rich educational background and a wealth of experience in the industry. He earned his PhD in Bioengineering from the prestigious University of Maryland and his BS in Chemical Engineering from the University of Notre Dame. He has held senior positions in Medcura, Inc. as both the Chief Scientific Officer and formerly as CEO at Remedium Technologies, Inc., where he championed research and development to offer cutting-edge biomedical solutions to the public.

As a bioengineering expert, Dowling spearheads research in therapeutic-targeted drug delivery, regenerative medicine, and medical device innovation. He also excels in providing scientific data and coaching to cross-functional teams of scientists and engineers to transform product concepts into market-ready healthcare technologies that are compliant with regulatory standards.

As a former Graduate Research Assistant at the University of Maryland, Dowling has been successful in leveraging cutting-edge technology and the latest research methodologies to make progress in areas such as nanotechnology, drug delivery, and drug discovery. He is also a prolific scientific writer, having authored several peer-reviewed journal articles and presented his research at multiple conferences nationwide.